FDA approves first self-administered flu vaccine
The vaccine FluMist, manufactured by MedImmune, which was acquired by AstraZeneca in 2007, was first approved by the FDA in 2003 for individuals between five and 49 years of age. Its approval has since been expanded to include children as young as two years old.
MedImmune Receives FDA Approval for Self-Administered Flu Vaccine
AstraZeneca's MedImmune has received Food and Drug Administration approval for FluMist, an influenza vaccine that can be administered either by oneself or by a healthcare provider.
FDA signals green light to game-changing flu vaccine spray
The FDA has approved the game-changing first flu vaccine spray that can be self-administered!On Friday, September 20, the United States Food and Drug Administration gave green light to AstraZeneca’s latest flu vaccine that can be used by
FDA Approves FluMist Nasal Spray Influenza Vaccine for Self- or Caregiver-Administration
First Influenza Vaccine That Does Not Need to be Administered by a Health Care Provider
FDA approves first flu vaccine that can be self-administered at home
"For those interested in self or caregiver administration, the vaccine manufacturer plans to make the vaccine available through a third-party online pharmacy," the FDA said. "Those who choose this option will complete a screening and eligibility assessment when they order FluMist.
FDA approves at-home FluMist administration
Through a third-party pharmacy, people interested in the self or caregiver option will complete a screening and eligibility assessment when they order the vaccine.
FDA Approves First Flu Vaccine You Give Yourself at Home
The days of waiting for a flu shot at your doctor's office or local pharmacy may be over: The U.S. Food and Drug Admi
FDA approves first nasal spray flu vaccine for use at home
The Food and Drug Administration on Friday approved the first at-home flu vaccine, a nasal spray that consumers with a prescription will be able to order online starting next year. Health experts say the convenience of the spray — FluMist — could lead to increased flu vaccination rates.
FDA approves ‘FluMist,' says no healthcare provider needed
FluMist is the first vaccine to prevent influenza that does not need to be administered by a healthcare provider, the regulator said.
MedPage Today12d
Twice-Yearly Biologic Cuts Severe Asthma Exacerbation Rate in Half
The phase IIIA trials randomized 792 patients ages 12 and older with severe asthma in a 2:1 ratio to depemokimab (100 mg ...
pharmaphorum10y
MedImmune completes $500m acquisition of Amplimmune
AstraZeneca's global biologics research and development arm, MedImmune, has completed its acquisition of Amplimmune, in a deal worth up to US $500 million. Amplimmune is a US-based biologics ...
cidrap.umn1d
Minnesota reports 2 H3N2v flu infections in fairgoers
The Minnesota Department of Health has reported two variant H3N2 (H3N2v) flu infections, both involving young people who ...
The News Journal4y
Pipeline full as MedImmune celebrates founding
When AstraZeneca acquired MedImmune in 2007 for $15 billion, some analysts felt the firm overpaid for the biotech company. This week, MedImmune celebrates its 25th anniversary – and has come to ...
University of Manchester1mon
MedImmune announces partnership to advance protein formulation science
MedImmune, the global biologics research and development arm of AstraZeneca, and The University of Manchester have entered into a new research collaboration to generate cutting-edge protein ...